Literature DB >> 7510243

Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages.

M M Stefani1, I Müller, J A Louis.   

Abstract

Lines of Leishmania major-specific CD8+ T cells were derived from the lymph nodes and spleens of CBA mice, immune following resolution of a primary infection, 7 days after secondary challenge with viable L. major. Specific stimulation of these CD8+ T cells by bone marrow-derived macrophages infected with L. major led to the release of interferon-gamma by CD8+ T cells and nitric oxide by macrophages. Interestingly, the nitric oxide released by bone marrow-derived macrophages down-regulated the production of interferon-gamma by specifically activated CD8+ T cells. The proliferation and long-term maintenance of these parasite-specific CD8+ T cells was impaired by the nitric oxide produced by stimulating infected macrophages as a result of cytokines released by activated stimulating infected macrophages as a result of cytokines released by activated CD8+ T cells. Taken together, the results indicate that L. major-specific CD8+ T cells are sensitive to the toxic effect of the nitric oxide that they induce.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510243     DOI: 10.1002/eji.1830240338

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity.

Authors:  Chittappen K Prajeeth; Simone Haeberlein; Heidi Sebald; Ulrike Schleicher; Christian Bogdan
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

2.  Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Authors:  Sylvie Bertholet; Alain Debrabant; Farhat Afrin; Elisabeth Caler; Susana Mendez; Khaled S Tabbara; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Central role for interleukin-4 in regulating nitric oxide-mediated inhibition of T-cell proliferation and gamma interferon production in schistosomiasis.

Authors:  Elisabeth A Patton; Anne C La Flamme; Joao A Pedras-Vasoncelos; Edward J Pearce
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 4.  Inducible nitric oxide synthase in inflammation.

Authors:  V Cattell; A Jansen
Journal:  Histochem J       Date:  1995-10

5.  Attenuated Salmonella vaccine-induced suppression of murine spleen cell responses to mitogen is mediated by macrophage nitric oxide: quantitative aspects.

Authors:  D Huang; M G Schwacha; T K Eisenstein
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

6.  Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers.

Authors:  M M Pompeu; C Brodskyn; M J Teixeira; J Clarêncio; J Van Weyenberg; I C Coelho; S A Cardoso; A Barral; M Barral-Netto
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

7.  Salmonella typhimurium infection in mice induces nitric oxide-mediated immunosuppression through a natural killer cell-dependent pathway.

Authors:  M G Schwacha; J J Meissler; T K Eisenstein
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation.

Authors:  Luiz Felipe D Passero; Ana Kely Carvalho; Maria Lac Bordon; Alexis Bonfim-Melo; Karina Carvalho; Esper G Kallás; Bianca Ba Santos; Marcos H Toyama; Adriana Paes-Leme; Carlos Ep Corbett; Márcia D Laurenti
Journal:  Parasit Vectors       Date:  2012-03-30       Impact factor: 3.876

Review 9.  Natural killer cells in experimental and human leishmaniasis.

Authors:  Christian Bogdan
Journal:  Front Cell Infect Microbiol       Date:  2012-05-29       Impact factor: 5.293

10.  CD8(+) T cells in leishmania infections: friends or foes?

Authors:  Simona Stäger; Sima Rafati
Journal:  Front Immunol       Date:  2012-01-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.